- $1.71bn
- $1.50bn
- $69.65m
Brief: Personalis Says On Nov 30, Co & Natera Agreed To Extend Date Through Which Natera Is Bound To Minimum Volume Commitments Under Deal With Co To 2024 End
Brief: Personalis Discloses Reduction In Headcount Impacting About 20% Of Co's Staff
Brief: Personalis Board Approved A Reduction In Company’S Workforce Of Up To 65 Employees
Brief: Personalis And Tempus Enter Into A Strategic Collaboration To Advance Cancer Testing
Brief: Personalis Q3 Net Income USD -29.098 Million
Personalis Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Personalis Says Analysis From Tracerx Study Reveals More Sensitive And Earlier Ctdna Detection In Lung Cancer Patients By Personalis' Mrd Technology
Brief: Personalis Inc Says On August 25, Received New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For Va's Million Veteran Program
Personalis Inc reports results for the quarter ended in June - Earnings Summary
Brief: Personalis, Inc. Q2 revenue USD 16.699 million
Personalis Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
Personalis Inc reports results for the quarter ended in March - Earnings Summary
Brief: Personalis Reports Q1 Loss Per Share $0.61
Brief: Personalis, ABRCC, and Criterium Announce Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
Personalis Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Personalis Selected For Clinical Research After Successful Evaluation Of Whole Genome-Based Molecular Residual Disease Assay
Brief: Personalis Appoints Christopher Hall As Chief Executive Officer
Brief: Personalis Reports Fourth Quarter And Full Year 2022 Financial Results